FATE THERAPEUTICS INC
FATE · XNASCIK 1434316fmd_17W3V5ZTRRG48RR5GDRZPSSCHYManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 63 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 4 | 5 | 11 | 31 | 56 | 96 | 64 | 14 | 7 |
| Research and development | 26 | 34 | 56 | 88 | 126 | 216 | 320 | 173 | 135 | 108 |
| Total operating expenses | 36 | 46 | 72 | 111 | 160 | 273 | 405 | 254 | 224 | 154 |
| Operating income | (32) | (42) | (67) | (101) | (128) | (217) | (308) | (191) | (210) | (148) |
| Interest expense | 2 | 1 | 2 | 2 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 1 | 2 | 4 | 2 | 1 | 6 | 17 | 17 | 11 |
| Other non-operating income (expense) | (1) | (1) | 0 | 3 | (45) | 5 | 27 | 30 | 24 | 11 |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (33) | (43) | (67) | (98) | (173) | (212) | (282) | (161) | (186) | (136) |